Pradžia › Plexiforminė neurofibroma › Merilendas
Plexiforminė neurofibroma klinikiniai tyrimai Merilendas
6 tyrimai dėl Plexiforminė neurofibroma ieško dalyvių vietose Merilendas.
Oficialus tyrimo tekstas (anglų kalba)
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
- National Institutes of Health Clinical Center, Bethesda
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius 5 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT02544022Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)
- National Institutes of Health Clinical Center, Bethesda
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 3 iki 120 · Visoms lytims · Atnaujinta 2026-09-02 · NCT06222203Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- National Institutes of Health Clinical Center, Bethesda
Renkami dalyviai1 fazė
Amžius nuo 3 iki 35 · Visoms lytims · Atnaujinta 2026-08-24 · NCT02390752A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
- Johns Hopkins Hospital, Baltimore
Renkami dalyviai2 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-07-29 · NCT06541847A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)
- National Institutes of Health Clinical Center, Bethesda
Renkami dalyviai
Amžius nuo 1 iki 120 · Visoms lytims · Atnaujinta 2026-06-09 · NCT06507748Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
- Johns Hopkins University, Baltimore
- National Cancer Institute/ National Institutes of Health, Bethesda
Renkami dalyviai2 fazė
Amžius nuo 1 iki 8 · Visoms lytims · Atnaujinta 2026-05-29 · NCT06188741Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.